The Effect of Thiazide, Amiloride and Hypertonic Saline on Urinary Biomarkers in Healthy Subjects (THAM)

Regional Hospital Holstebro

Status: Completed

Conditions: Nephropathy

Treatments: Other: hypertonic saline

Study type: Interventional

Funder types: Other

Identifiers

NCT01635231

EBP-JMJ-2012-1

Details and patient eligibility

About

Urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2) reflects the activity of the sodium- and water channels in the human kidney.

Changes in the sodium-and water channel activity can be induced by blocking the sodium channels with diuretics in healthy subjects

Full description

1. Urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2) reflects the kidneys transport of sodium and water in the nephron.
2. Changes in the sodium-and water channel activity is induced by blocking the NCC channels with thiazide and ENaC channels with amiloride and by intervention with hypertonic NaCl The changes in sodium-and water channels are followed by changes in extracellular and intracellular fluids, central bloodpressure and the plasma concentration of vasoactive hormones.

The purpose of this study is to investigate the changes in urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2), extra- and intracellular fluid compartments, central bloodpressure and the plasma concentration of Vasoactive hormones in healthy subjects under a) treatment with Amiloride and Thiazide at baseline and b) after and acute infusion with hypertonic saline.

Subjects will be examined on three examination days. Four days prior to the examination days the subjects will consume a standard diet based on amount of sodium and calories and randomized to treatment with either thiazide, amiloride or placebo twice daily for 5 days. On the examination days the subjects receive an infusion with hypertonic saline.

Renal function is measured by renal clearance of 51Cr-EDTA. Urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2) will be measured to evaluate the activity of water- and sodium channels in the nephron, changes in fluid compartments are measured by body composition monitor. Central blood pressure is measured by sphygmocor.

Enrollment: 24 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy males and females
• age 18-45
• BMI range 18,5-30,0 kg/m2

Exclusion criteria

• hypertension (i.e. ambulatory BP > 130 mmHg systolic or/and > 80 mmHg diastolic)
• history or clinical significant signs of heart, lung, liver, kidney, endocrine, brain or neoplastic
• disease.
• alcohol abuse
• drug abuse
• smoking
• pregnancy or nursing
• blood donation within a month prior to examination
• medical treatment apart from oral contraception abnormal blood samples, -ECG and -urine dipstick, drug abuse, alcohol abuse, pregnancy, medication

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

24 participants in 3 patient groups, including a placebo group

thiazide, diuretic

Active Comparator group

Description:

1.25 mg thiazide twice daily for 5 days

Treatment:

Other: hypertonic saline

amiloride, diuretic

Active Comparator group

Description:

5 mg of amiloride twice daily

Treatment:

Other: hypertonic saline

calcium

Placebo Comparator group

Description:

placebo twice daily for 5 days

Treatment:

Other: hypertonic saline